News | December 09, 2024
Suven to acquire 56% stake in ADC specialist NJ Bio for US$64.4 million
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Aragen Life Sciences is the first Indian CRDMO to receive SBTi approval
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Executes the first project for developing and manufacturing a novel anticancer mAb
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
Subscribe To Our Newsletter & Stay Updated
